Trying to learn how to translate from the human translation examples.
From: Machine Translation
Suggest a better translation
Quality:
From professional translators, enterprises, web pages and freely available translation repositories.
metacam was effective from day 0–14 compared to the control group.
liek metacam bol účinný od dňa 0 – 14 v porovnaní s kontrolnou skupinou.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
a statistically significant increase in 6mwd was observed in all 3 sildenafil dose groups compared to those on placebo.
vo všetkých troch skupinách so sildenafilom bolo v porovnaní so skupinami s placebom zaznamenané štatisticky významné predĺženie 6mwd.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
results demonstrated a statistically significant reduction in polyp burden in all celecoxib treatment groups compared to the corresponding placebo treatment groups.
výsledky ukázali štatisticky významné zníženie polypovej záťaže vo všetkých skupinách liečených celekoxibom v porovnaní s príslušnými skupinami liečenými placebom.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
the median time on treatment was approximately 70 months in the nilotinib treatment groups and 64 months in the imatinib group.
medián trvania liečby bol približne 70 mesiacov v skupinách liečby nilotinibom a 64 mesiacov v skupine imatinibu.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
in the imatinib arm, patients were treated with 400 mg daily.
v skupine imatinibu pacienti dostávali dávku 400 mg denne.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
# p < 0.05 dulaglutide treatment group compared to liraglutide.
# p < 0,05, ## p < 0,001 liečebná skupina s dulaglutidom v porovnaní s inzulínom glargínom
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Warning: Contains invisible HTML formatting
a different spectrum of mutation was detected in the imatinib treatment arm.
v ramene liečenom imatinibom sa detekovalo iné spektrum mutácií.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
a higher frequency of headache was reported in this age group compared to the children, adults and elderly.
vyššia frekvencia výskytu bolesti hlavy bola hlásená v tejto vekovej skupine v porovnaní s deťmi, dospelými a staršími osobami.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
the median time from diagnosis to randomisation was 64 months in the dasatinib group and 52 months in the imatinib group.
medián času od stanovenia diagnózy po randomizáciu bol 64 mesiacov v skupine s dasatinibom a 52 mesiacov v skupine s imatinibom.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
reduction in the rate of progression of structural damage was observed at weeks 30 and 54 in the infliximab + methotrexate groups compared to methotrexate alone.
po 30 a 54 týždňoch sa v skupinách s infliximabom + metotrexátom pozorovala redukcia stupňa progresie štrukturálneho poškodenia, v porovnaní so samotným metotrexátom.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
a statistically significantly greater proportion of patients in the sprycel group achieved a cccyr compared with patients in the imatinib group within the first 12 months of treatment.
Štatisticky významne väčší podiel pacientov v sprycelovej skupine dosiahol cccyr v priebehu prvých 12 mesiacov liečby v porovnaní s pacientmi v imatinibovej skupine.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
3.4% in the orlistat group compared to 5.4% in the placebo-treated group).
3, 4% v skupine s orlistatom v porovnaní s 5, 4% v skupine dostávajúcej placebo).
Last Update: 2012-04-12
Usage Frequency: 2
Quality:
the main secondary endpoint was mcyr by total daily dose level in the imatinib-resistant patients.
mcyr bola hlavným sekundárnym koncovým ukazovateľom pri celkovej dennej dávke u pacientov rezistentných na imatinib.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
# p < 0.05, ## p < 0.001 dulaglutide treatment group compared to metformin
# p < 0,05 liečebná skupina s dulaglutidom v porovnaní s liraglutidom.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Warning: Contains invisible HTML formatting
statistically significant differences from placebo (p<0.05) were observed for improvements in the total signs and symptoms score for all dose groups compared to placebo.
Štatisticky významné rozdiely oproti placebu (p < 0,05) sa zistili pri zlepšení celkového skóre znakov a príznakov vo všetkých dávkových skupinách v porovnaní s placebom.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Warning: Contains invisible HTML formatting
# p < 0.05, ## p < 0.001 dulaglutide treatment group compared to insulin glargine
# p < 0,05; ## p < 0,001 liečebná skupina s dulaglutidom v porovnaní s inzulínom glargínom
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Warning: Contains invisible HTML formatting
52-week treatment period, haemoglobin remained relatively stable in the fexeric group compared to the active control group (table 4).
52-týždňového obdobia liečby zostal hemoglobín v skupine s liekom fexeric v porovnaní so skupinou s aktívnou kontrolnou látkou relatívne stabilný (tabuľka 4).
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
improvements from baseline hba1c were sustained in the saxagliptin add-on to insulin group compared to the placebo add-on to insulin group with or without metformin at week 52.
v 52. týždni trvalé zlepšenie oproti východiskovej hodnote hba1c bolo v skupine so saxagliptínom pridaným k inzulínu v porovnaní so skupinou s placebom pridaným k liečbe inzulínom s metformínom alebo bez neho.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
survival through 3 months was also better in the xigris group compared to placebo (log rank p=0.048).
prežívanie počas 3 mesiacov bolo tiež vyššie v skupine, ktorá dostala xigris v porovnaní s placebovou skupinou (log rank p=0,048).
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
dry mouth, the only very common event, occurred with a frequency of 28.8% in the fesoterodine group compared to 8.5% in the placebo group.
sucho v ústach, jediný veľmi častý nežiaduci účinok, sa vyskytlo u 28, 8% pacientov v skupine liečenej fesoterodínom v porovnaní s 8, 5% v skupine v ktorej sa podávalo placebo.
Last Update: 2012-04-12
Usage Frequency: 2
Quality:
Some human translations with low relevance have been hidden.
Show low-relevance results.